Literature DB >> 17452424

Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.

Mariano Hurtado1, Juan José Lozano, Elisabeth Castellanos, Luis A López-Fernández, Keith Harshman, Carlos Martínez-A, Angel R Ortiz, Timothy M Thomson, Rosanna Paciucci.   

Abstract

BACKGROUND: Tissue plasminogen activator (tPA) is the major activator of plasminogen in plasma. This serine protease is overexpressed by exocrine pancreas tumour cells, where it promotes tumour cell proliferation, growth, and invasion. Here we have explored the signalling pathways used by tPA to activate the proliferation of pancreatic cancer cells.
METHODS: Transcriptional profiling on cDNA micro arrays was used to analyse the pattern of gene expression in response to tPA compared to the response to epidermal growth factor (EGF) and platelet derived growth factor (PDGF). Results were confirmed using different biochemical assays in which specific kinase inhibitors or RNA interference were used.
RESULTS: Transcriptional profiling showed that tPA modulates the expression of a set of genes commonly regulated by EGF, but distinct from the major set of genes modulated by PDGF. This suggested that tPA and EGF share common signalling pathways, a conclusion supported by further experimental evidence. Firstly, we found that tPA induced a rapid and transient phosphorylation of the EGFR. Secondly, specific EGFR kinase inhibitors, but not PDGFR kinase inhibitors, abolished the tPA induced phosphorylation of the ERK1/2 kinases and cell proliferation. The mitogenic activity of tPA was also inhibited by siRNA depletion of EGFR, thus confirming the involvement of this receptor in tPA triggered signalling. Thirdly, we show that the signalling and mitogenic effects of tPA require its proteolytic activity, the activity of the metalloprotease-9 and active hb-EGF.
CONCLUSION: Our results suggest that tPA induces proliferation by triggering a proteolytic cascade that sequentially activates plasmin, metalloprotease-9 (MMP-9) and hb-EGF. These events are required to activate the EGFR signalling pathway and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452424      PMCID: PMC1954978          DOI: 10.1136/gut.2006.097188

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  64 in total

1.  Functional discovery via a compendium of expression profiles.

Authors:  T R Hughes; M J Marton; A R Jones; C J Roberts; R Stoughton; C D Armour; H A Bennett; E Coffey; H Dai; Y D He; M J Kidd; A M King; M R Meyer; D Slade; P Y Lum; S B Stepaniants; D D Shoemaker; D Gachotte; K Chakraburtty; J Simon; M Bard; S H Friend
Journal:  Cell       Date:  2000-07-07       Impact factor: 41.582

2.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF.

Authors:  N Prenzel; E Zwick; H Daub; M Leserer; R Abraham; C Wallasch; A Ullrich
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  FAK integrates growth-factor and integrin signals to promote cell migration.

Authors:  D J Sieg; C R Hauck; D Ilic; C K Klingbeil; E Schaefer; C H Damsky; D D Schlaepfer
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

4.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Authors:  O Nicole; F Docagne; C Ali; I Margaill; P Carmeliet; E T MacKenzie; D Vivien; A Buisson
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

5.  Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.

Authors:  M S Stack; R D Gray; S V Pizzo
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

6.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.

Authors:  M Korc; B Chandrasekar; Y Yamanaka; H Friess; M Buchier; H G Beger
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

7.  Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone.

Authors:  Susanne Roelle; Robert Grosse; Achim Aigner; H W Krell; Frank Czubayko; Thomas Gudermann
Journal:  J Biol Chem       Date:  2003-09-08       Impact factor: 5.157

8.  Increased soluble EGF after ischemia is accompanied by a decrease in membrane-associated precursors.

Authors:  R P Schaudies; J P Johnson
Journal:  Am J Physiol       Date:  1993-03

9.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness.

Authors:  Y Yamanaka; H Friess; M S Kobrin; M Buchler; H G Beger; M Korc
Journal:  Anticancer Res       Date:  1993 May-Jun       Impact factor: 2.480

10.  Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.

Authors:  K Akassoglou; K W Kombrinck; J L Degen; S Strickland
Journal:  J Cell Biol       Date:  2000-05-29       Impact factor: 10.539

View more
  14 in total

1.  Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.

Authors:  M G Martínez-Hernández; L A Baiza-Gutman; A Castillo-Trápala; D Randall Armant
Journal:  Reproduction       Date:  2010-11-12       Impact factor: 3.906

2.  IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells.

Authors:  Ching-Yi Cheng; Chang-Ting Kuo; Chih-Chung Lin; Hsi-Lung Hsieh; Chuen-Mao Yang
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.

Authors:  Fatma H Al-Awadhi; Brian K Law; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2017-10-31       Impact factor: 4.050

Review 4.  Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.

Authors:  M Mimeault; S K Batra
Journal:  Gut       Date:  2008-10       Impact factor: 23.059

Review 5.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 6.  New Insights into Diabetes Cell Therapy.

Authors:  Philippe A Lysy; Elisa Corritore; Etienne M Sokal
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

7.  Inhibition of progression of PanIN through antagonizing EGFR.

Authors:  Xiaojun He; Hui Zhang; Mei Xiao; Yalin Kong; Wenbing Li; Hongyi Zhang
Journal:  Tumour Biol       Date:  2014-12-18

Review 8.  Molecular biology of pancreatic cancer.

Authors:  Cristóbal Belda-Iniesta; Immaculada Ibáñez de Cáceres; Jorge Barriuso; Javier de Castro Carpeño; Manuel González Barón; Jaime Feliú
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

9.  Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.

Authors:  Mark W Gramling; Lea M Beaulieu; Frank C Church
Journal:  Exp Cell Res       Date:  2009-11-03       Impact factor: 3.905

Review 10.  Novel actions of tissue-type plasminogen activator in chronic kidney disease.

Authors:  Kebin Hu; Wendy M Mars; Youhua Liu
Journal:  Front Biosci       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.